The Society of Nuclear Medicine is proud to count on the following organisations as Corporate Sponsors of the Society. Their support demonstrates a commitment to make an impact on the advancement of clinical practice, research and public education in Nuclear Medicine.
GE Healthcare is a leading global medical technology and digital solutions innovator. GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 50,000 employees globally, the company operates at the centre of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world. www.gehealthcare.com.au/
ANSTO is the home of Australia's most significant landmark and national infrastructure for research. Thousands of scientists from industry and academia benefit from gaining access to state-of-the-art instruments every year.
ANSTO manufactures and supplies a range of radiopharmaceuticals, radiochemicals, kits and accessories for use in research, industry and the health sector.
Further information is available at www.ansto.gov.au
Qscan Radiology Clinics is a comprehensive Diagnostic Medical Imaging & Interventional practice with multiple clinics in South-East Queensland and additional Qscan Group partner clinics elsewhere in Australia. We are a dynamic organisation driven by clarity of vision and values that focus on providing compassionate care for our patients and excellence for our referrers.
These healthcare objectives are achieved through our subspecialty trained Radiologists and highly trained clinical and support staff. We utilise the latest information technology and state of the art medical imaging equipment.
Telix Pharmaceuticals was created to deliver on the promise of nuclear medicine.
The field of nuclear medicine has historically lacked clinical momentum and commitment to late-stage product development. Our goal is to rectify this for the benefit of patients.
Clarity Pharmaceuticals is a personalised medicine company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing targeted therapies for the treatment of cancer and other serious diseases in adults and children.
Clarity is the first company to develop the perfect pairing of next-generation theranostic (therapeutic and diagnostic) products using two isotopes of copper. Clarity's lead compound, SARTATE™, is in clinical development focused on neuroblastoma and neuroendocrine tumours. Following excellent pre-clinical data on its SAR-bisPSMA product, the prostate cancer market is a key focus for Clarity, with clinical trials planned for 2020. Clarity’s technology holds great promise of improving prostate cancer diagnosis and treatment and has the potential to provide multiple benefits in comparison to current products. Clarity’s SAR-BBN product is also entering clinical development in 2020 in patients with breast and prostate cancer. SAR-BBN is a pan cancer target that holds the potential of improving treatment outcomes in such large patient indications such as prostate, ovarian and breast cancer.
Gammasonics Institute for Medical Research Pty Ltd is recognised worldwide for innovative research and design utilising technology in the areas of radiation protection, measurement and detection.
Gammasonics invests directly towards the integration of technology, implementation of advanced medical science and manufacturing technologies, as well as into development
Cyclomedica is an established Australian radiopharmaceutical company servicing the global medical community since 1986.
Cyclomedica is a company in the diagnostic imaging field specialising in lung health. We achieve this positioning through our proprietary medical device and pharmaceutical products under the name of Technegas™ which has become the industry gold-standard in diagnostic functional lung imaging technology.
We distribute our products in 60 countries throughout the world with over 1500 nuclear medicine departments utilising Technegas™. To date, over 4.2 million patient procedures are recorded worldwide.